Conditions: Moderate to Severe Plaque-type Psoriasis
Keywords: Psoriasis plaque inflammatory skin disease scaly patches AIN457 secukinumab Moderate to Severe Plaque-type Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 967
Healthy volunteers: no

Brief summary:
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

Detailed description:

Arms:
arm 1: secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO) arm 2: secukinumab- 2 x 150mg injections per dose arm 3: 1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection arm 4: 2 s.c. secukinumab 150 mg injections arm 5: 1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection arm 6: 2 s.c. secukinumab 150 mg injections

Interventions: intervention 1: AIN457 150mg intervention 2: AIN457 300mg
Intervention descriptions: intervention 1: (1 injection per dose) and placebo to secukinumab 150 mg intervention 2: secukinumab 150 mg (2 injections per dose)

Protocol document: